Steven John Durrant

This inventor holds 71 USPTO granted patents and 28 published patent applications, plus 2 CIPO patents and 26 EPO patents, primarily in ATR Kinase Inhibitors (CPC class C07D). Top assignees: Vertex Pharmaceuticals, Inc., Merck Patent Gmbh, Other. Active years: 2010-2026.

USPTO Granted Patents = 71 (Patent Applications = 28)

% Patents Active = 46.5

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 26 (Patent Applications = 37)

Average Co-Inventor Count = 7.0

ph-index = 18

Forward Citations = 707(Granted Patents)

Forward Citations (Not Self Cited) = 451(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Abingdon, Oxfordshire, GB (2010)
Oxfordshire, GB (2012)
Abingdon, GB (2010 - 2024)
Headington, GB (2023 - 2024)

Company Filing History:

70 out of 1,167

Vertex Pharmaceuticals, Inc.

1 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

ATR Kinase

Sodium Channels

Tetrahydrofuran

Inhibitors

Pyrazines

Carboxamides

Protein Kinases

GCN2

Compounds

Processes

Synthesis

Heteroaryl

71 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12662470 - Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels (2026-06-23),

2. 12258333 - N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels (2025-03-25),

3. 12247021 - Substituted tetrahydrofurans as modulators of sodium channels (2025-03-11),

4. 12187731 - Compounds useful as inhibitors of ATR kinase (2025-01-07),

5. 12084438 - GCN2 inhibitors and uses thereof (2024-09-10),

6. 11919887 - Substituted tetrahydrofurans as modulators of sodium channels (2024-03-05),

7. 11834441 - Substituted tetrahydrofurans as modulators of sodium channels (2023-12-05),

8. 11827627 - N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels (2023-11-28),

9. 11370798 - Compounds useful as inhibitors of ATR kinase (2022-06-28),

10. 11117900 - Compounds useful as inhibitors of ATR kinase (2021-09-14),

11. 10988477 - GCN2 inhibitors and uses thereof (2021-04-27),

12. 10961232 - Substituted pyrazines as ATR kinase inhibitors (2021-03-30),

13. 10822331 - Processes for preparing ATR inhibitors (2020-11-03),

14. 10793563 - GCN2 inhibitors and uses thereof (2020-10-06),

15. 10787452 - Compounds useful as inhibitors of ATR kinase (2020-09-29),

Title: Exploring the Innovations of Inventor Steven John Durrant

Introduction:

Steven John Durrant, a prolific inventor hailing from Headington, GB, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 66 patents.

Latest Patents:

Among his recent patents is the groundbreaking invention titled "Substituted tetrahydrofurans as modulators of sodium channels." These compounds and their pharmaceutically acceptable salts have showcased potential as inhibitors of sodium channels, offering novel treatment avenues for various disorders, particularly in the realm of pain management.

Career Highlights:

Throughout his career, Steven John Durrant has been associated with renowned companies such as Vertex Pharmaceuticals, Inc. and Merck Patent GmbH, where he has honed his expertise in pharmaceutical innovation and patent development.

Collaborations:

In his professional journey, Steven has collaborated with esteemed colleagues like Jean-Damien Charrier and Ronald Marcellus Knegtel, fostering a culture of innovation and excellence within the pharmaceutical research landscape.

Conclusion:

Inventor Steven John Durrant's relentless pursuit of innovation and pioneering spirit in the field of pharmaceuticals underscore his commitment to advancing healthcare solutions. His patents stand as a testament to his ingenuity and dedication to improving the quality of life for individuals worldwide.